Results 41 to 50 of about 1,234 (179)
PF683 ARTERIAL THROMBOSIS IN YOUNG PV PATIENTS
HemaSphere, Volume 3, Issue S1, Page 295-296, June 2019., 2019 Background: Polycythemia Vera (PV) is a myeloproliferative neoplasm mainly affecting median advanced age while rarely occurs in young patients. PV natural history is marked by vascular complications and studies exploring the thrombotic events and their management in young PV patient are lacking. Aims: The purpose of the present study is to evaluate the
G. Bogoni +5 more
wiley +1 more source
Abstract Book for the 27th Congress of the European Hematology Association
, 2022 HemaSphere, Volume 6, Issue S3, Page 1-4130, June 2022.
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 296, June 2019., 2019 Background: In patients with essential thrombocythemia (ET) who have high risk factors for thrombotic events, cytoreductive therapy with anagrelide (ANA) or hydroxycarbamide (HC) is one of the treatment options. Despite the clinically evident platelet‐lowering effect of ANA, the detailed mechanism of its effect remains to be elucidated.
N. Miyashita +4 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 296-297, June 2019., 2019 Background: Essential thrombocythemia (ET) is a BCR‐ABL1‐negative myeloproliferative neoplasm associated in 50–60% of cases with the presence of the JAK2V617F mutation. Several studies have revealed that oxidative stress induces a growth advantage to JAK2V617F‐ positive clones, but little is known about the antioxidant status of ET patients.
M.‐A. Gaman, C. Moisa, A.M. Gaman
wiley +1 more source
Helena Antipoff e a Sociedade Pestalozzi de Minas Gerais: filantropia e ciência em prol dos anormais [PDF]
História, Ciências, Saúde: ManguinhosResumo A relação entre filantropia, poder público e conhecimento científico é analisada a partir da experiência de Helena Antipoff na Sociedade Pestalozzi de Minas Gerais. Essa instituição promoveu, na primeira metade do século XX, iniciativas de auxílio
Adriana Araújo Pereira Borges +1 more
doaj +2 more sources
EHA2021 Virtual Congress Abstract Book
, 2021 HemaSphere, Volume 5, Issue S2, June 2021.
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 874-875, June 2019., 2019 Background: Ponatinib (PON) is a third generation tyrosine kinase inhibitor (TKI) used in adults with chronic myeloid leukaemia (CML) or Ph+ acute lymphoblastic leukaemia who are resistant or intolerant to prior TKIs or those harbouring the BCR‐ABL1T315I mutant.
F.‐E. Nicolini +7 more
wiley +1 more source
CHALLENGES IN THE DIAGNOSIS OF PEDIATRIC PNEUMONIA [PDF]
Romanian Journal of Pediatrics, 2016 Pneumonia is a form of acute respiratory infection that affects the lungs and it is the leading cause of illness and death in children worldwide. Pneumonia can occur at any age, but it is more common in younger children.
Ligia Georgeta Stanescu +7 more
doaj +1 more source
HemaSphere, Volume 3, Issue S1, Page 875, June 2019., 2019 Background: In a developing economy like India, Imatinib usage has increased manifold after generic formulations were introduced. 25 brands of generic Imatinib are approved by the Drug Controller General of India. The efficacy and safety of these brands have been repeatedly questioned by different studies.
A. Iqbal +4 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 875-876, June 2019., 2019 Background: Chronic myeloid leukaemia (CML) is a chronic myeloproliferative neoplasm associated with a BCR‐ABL1 gene sequence. Some studies have shown that oxidative stress is involved in CML pathogenesis, genomic instability, disease progression and resistance to tyrosine‐kinase inhibitors (TKI).
E.G. Pascu, M.‐A. Gaman, A.M. Gaman
wiley +1 more source